Found: 9
Select item for more details and to access through your institution.
Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure.
- Published in:
- Life (2075-1729), 2023, v. 13, n. 9, p. 1841, doi. 10.3390/life13091841
- By:
- Publication type:
- Article
Impact of IPSS-M implementation in real-life clinical practice.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1199023
- By:
- Publication type:
- Article
IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies.
- Published in:
- European Journal of Haematology, 2020, v. 105, n. 5, p. 597, doi. 10.1111/ejh.13493
- By:
- Publication type:
- Article
Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia.
- Published in:
- Therapeutic Advances in Hematology, 2021, v. 12, p. 1, doi. 10.1177/20406207211039326
- By:
- Publication type:
- Article
P-226: Clinical outcomes of Multiple Myeloma patients after anti-CD38 monoclonal antibodies failure.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S164, doi. 10.1016/S2152-2650(21)02353-3
- By:
- Publication type:
- Article
P-148: Real-life analysis of the multiple myeloma patient's survival in a third-level hospital.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S116, doi. 10.1016/S2152-2650(21)02275-8
- By:
- Publication type:
- Article
Octogenarians with chronic kidney disease in the nephrology clinic: Progressors vs. non-progressors.
- Published in:
- Frontiers in Nephrology, 2023, v. 3, p. 1, doi. 10.3389/fneph.2023.1114486
- By:
- Publication type:
- Article
Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter